Skip to Content

Votrient (pazopanib) Disease Interactions

There are 11 disease interactions with Votrient (pazopanib):

Major

Pazopanib (applies to Votrient) bleeding

Major Potential Hazard, Moderate plausibility. Applicable conditions: Gastrointestinal Hemorrhage

Pazopanib may increase the risk of bleeding. Patients who have a history of hemoptysis, cerebral hemorrhage or those who have experienced clinically significant gastrointestinal hemorrhage in the past 6 months should not use this agent.

Major

Pazopanib (applies to Votrient) liver dysfunction

Major Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Severe and fatal hepatotoxicity has been observed with the use of pazopanib. No dose adjustment is required in patients with mild hepatic impairment. Pazopanib dose should be reduced to 200 mg per day in patients with moderate hepatic impairment. Pazopanib is not recommended in patients with severe hepatic impairment. It is recommended to monitor serum liver tests before starting treatment with pazopanib and at weeks 3, 5, 7, and 9. Thereafter, monitor at month 3 and at month 4, and as clinically indicated; periodic monitoring should then continue monthly. The use of this agent should be interrupted in patients presenting significant hepatic dysfunction and restart therapy only if clinically necessary and according to clinical recommendations.

Major

VEGFR (applies to Votrient) GI perforation

Major Potential Hazard, Moderate plausibility. Applicable conditions: Gastrointestinal Perforation, Gastrointestinal Obstruction, History - Radiation Therapy

Inhibitors of vascular endothelial growth factor receptors (VEGFR) may cause gastrointestinal perforation and fistulae. Avoid use of these agents in patients with ovarian cancer who have evidence of recto-sigmoid involvement by pelvic examination or bowel involvement on CT scan or clinical symptoms of bowel obstruction. Permanently discontinue these agents in patients with gastrointestinal perforation.

Moderate

Pazopanib (applies to Votrient) CV disease

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Cardiovascular Disease, Congestive Heart Failure

Patients should be carefully monitored for clinical signs or symptoms of congestive heart failure. Baseline and periodic evaluation of LVEF is recommended in patients at risk of cardiac dysfunction including previous anthracycline exposure.

Moderate

Pazopanib (applies to Votrient) hypothyroidism

Moderate Potential Hazard, Moderate plausibility.

Hypothyroidism has been reported in patients taking pazopanib. Therapy with pazopanib should be administered cautiously to patients with thyroid dysfunction. Baseline laboratory measurement of thyroid function is recommended and if appropriate, treatment per standard medical practice should be given prior to initiation of therapy. Clinical monitoring of thyroid function is recommended during therapy.

Moderate

Pazopanib (applies to Votrient) lung dysfunction

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Interstitial Pneumonitis, Pulmonary Impairment

Interstitial Lung Disease (ILD)/Pneumonitis has been reported with the use of pazopanib. Monitor patients for pulmonary symptoms indicative of ILD/pneumonitis and discontinue pazopanib in patients developing ILD or pneumonitis.

Moderate

Pazopanib (applies to Votrient) QT prolongation

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Long QT Syndrome

Pazopanib can cause QT prolongation which may lead to an increased risk for ventricular arrhythmias, including Torsade de Pointes. This agent should be administered with caution in patients with a history of QT interval prolongation, in patients taking antiarrhythmics or other medications that may prolong QT interval. Serum electrolytes should be corrected before initiating therapy with this agent. Periodic monitoring of ECGs and electrolytes is recommended in these patients.

Moderate

VEGFR (applies to Votrient) hypertension

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Hypertensive Encephalopathy

Inhibitors of vascular endothelial growth factor receptors (VEGFR) have been associated with severe increases in blood pressure. Therapy with these agents should be administered cautiously in patients with preexisting hypertension. Blood pressure should be assessed prior to initiating treatment, regularly during treatment and after discontinuation in patients with bevacizumab -induced or -exacerbated hypertension. Temporarily suspend these agents in patients with severe hypertension that is not controlled with medical management. Discontinue these agents in patients with hypertensive crisis or hypertensive encephalopathy.

Moderate

VEGFR (applies to Votrient) PRES

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Posterior Reversible Encephalopathy Syndrome

Posterior Reversible Encephalopathy Syndrome (PRES) has been reported with the use of inhibitors of vascular endothelial growth factor receptors (VEGFR) in clinical studies. PRES is a neurological disorder which can present with headache, seizure, lethargy, confusion, blindness and other visual and neurologic disturbances. It is recommended to discontinue these agents in patients developing PRES. The safety of restarting therapy is not known. Cation is recommended if therapy is reinitiating in patients previously experiencing PRES.

Moderate

VEGFR (applies to Votrient) proteinuria

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

The incidence and severity of proteinuria is increased in patients taking inhibitors of vascular endothelial growth factor receptors (VEGFR). Therapy with these agents should be administered cautiously in patients with renal dysfunction. Monitoring for proteinuria and hematuria is recommended and perform baseline and periodic urinalyses during treatment, with follow up measurement as clinically indicated. It is recommended to temporarily suspend these agents in patients with moderate to severe proteinuria and to discontinue therapy in patients with nephrotic syndrome.

Moderate

VEGFR (applies to Votrient) thromboembolic disorders

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Pulmonary Embolism, Thrombotic/Thromboembolic Disorder, History - Thrombotic/Thromboembolic Disorder

Venous and arterial thromboembolic events (VTE and ATE), some fatal, have been reported with the use of inhibitors of vascular endothelial growth factor receptors (VEGFR). Caution is recommended when using these agents in patients with a reported history of VTE or ATE. These agents should be discontinued in patients with serious or life-threatening VTE or ATE, including pulmonary embolism.

Votrient (pazopanib) drug interactions

There are 557 drug interactions with Votrient (pazopanib)

Votrient (pazopanib) alcohol/food interactions

There is 1 alcohol/food interaction with Votrient (pazopanib)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.